BioAxone BioSciences Appoints Ronald S. Goldstein as CFO

Published: Apr 10, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BioAxone BioSciences, Inc., an emerging clinical-stage biotechnology company focused on developing innovative drugs to restore neurological function, today announced the appointment of Ronald S. Goldstein, MBA, CPA, as Chief Financial Officer.
 
Mr. Goldstein brings strategic planning expertise as well as hands-on corporate finance experience including accounting, taxation and audit management. His background includes public accounting rules and presentation, SEC reporting and regulations and working with the banking and investment communities. Companies with whom he has worked include NKT Therapeutics and Cyteir Therapeutics, as well as Tufts NE Medical Center and, earlier in his career, SLI, Inc., which grew from a small, specialized manufacturer into a public traded, vertically integrated worldwide manufacturer and OEM supplier to the lighting industry.
 
“We are thrilled to add Ron to our team at BioAxone and believe that he can have a positive impact on where we see ourselves in the future,” said Lisa McKerracher, CEO, BioAxone BioSciences. “Ron has experience leading companies small and large in different industries, including biotech, and we will utilize his skills to continue helping BioAxone grow and care for patients with CNS disorders.”
 
“I was motivated to work with BioAxone to ensure the necessary financial underpinning to help bring the company’s pipeline of drug candidates to development. In my discussions with Lisa and the team, their scientific expertise in combination with business acumen was very clear,” said Goldstein. “I am eager to work with the team as we position the company for continued success.”
 
Mr. Goldstein received his BS/BA, Accounting and MBA, Finance at Boston University. He is also a member of the Massachusetts Society of CPAs and the American Institute of CPAs (AICPA).
 
About BioAxone BioSciences
BioAxone BioSciences is a clinical-stage biotechnology company based in Cambridge, MA, and is developing innovative drugs to restore neurological function for patients with Spinal Cord Injuries (SCI) and vascular malformations in the central nervous system with unmet medical need, and glaucoma. BioAxone is led by a team of scientists renowned for their work on axon regeneration and neuronal signaling pathways. For more information, visit http://www.bioaxonebio.com and follow the company on Twitter at @BioAxone.

 

Contacts

LaVoieHealthScience
Beth Kurth, 617-374-8800 Ext. 106
bkurth@lavoiehealthscience.com

 
 

Source: BioAxone BioSciences, Inc.

Back to news